Feigelson H S, McKean-Cowdin R, Pike M C, Coetzee G A, Kolonel L N, Nomura A M, Le Marchand L, Henderson B E
Department of Preventive Medicine, University of Southern California School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles 90033-0800, USA.
Cancer Res. 1999 Aug 15;59(16):3908-10.
We investigated whether a polymorphism in the cytochrome P450c17alpha gene (CYP17), which is associated with higher endogenous hormone levels, influences the use of hormone replacement therapy (HRT). The study included 749 postmenopausal women ages 44-75 years at baseline randomly selected from a larger multiethnic cohort. African-American, Japanese, Latina, and white women were included in the study. Women who carry the CYP17 A2/A2 genotype were about half as likely as women with the A1/A1 genotype to be current HRT users (odds ratio = 0.52; 95% confidence interval, 0.31-0.86). This association was present in all four racial/ethnic groups and for women above and below the median weight of 150 pounds. These findings suggest that the actual risk of breast cancer associated with HRT use may be higher than previously reported.
我们研究了细胞色素P450c17α基因（CYP17）中的一种多态性是否会影响激素替代疗法（HRT）的使用，该多态性与较高的内源性激素水平相关。该研究纳入了749名年龄在44 - 75岁之间的绝经后女性，她们在基线时从一个更大的多民族队列中随机选取。研究对象包括非裔美国女性、日本女性、拉丁裔女性和白人女性。携带CYP17 A2/A2基因型的女性成为当前HRT使用者的可能性约为携带A1/A1基因型女性的一半（优势比 = 0.52；95%置信区间，0.31 - 0.86）。这种关联在所有四个种族/族裔群体中以及体重高于和低于150磅中位数的女性中均存在。这些发现表明，与使用HRT相关的乳腺癌实际风险可能高于先前报道的风险。
